June 7, 2021 — A couple years ago a study showed a mortality safety signal in patients who underwent peripheral artery disease (PAD) revascularization with paclitaxel drug-coated devices. This immediately raised alarm in with the U.S. Food and Drug Administration (FDA) and the interventional community and prompted numerous studies to confirm if there was a mortality signal, or if the findings were just coincidence.
